Encephalomalacia Market Share

Encephalomalacia Market Overview

Encephalomalacia Market Size was valued at USD 0.3 Billion in 2023. The Global Encephalomalacia industry is projected to grow from USD 0.4 Billion in 2024 to USD 0.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.20% during the forecast period (2024 - 2032).Softening or loss of brain tissue is termed as encephalomalacia and is a severe type of brain damage. Encephalomalacia disorder can also be classified into the three categories depending on their colors and the stages of damage i.e. red softening yellow softening, and white softening.

The major causes of encephalomalacia are inflammation or hemorrhages that are a consequence of being afflicted by cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or another injury. Moreover, stroke is the most commonly known cause of encephalomalacia and stroke can be caused by either a head injury or a brain hemorrhage or both of them cause internal bleeding in brain. 

Furthermore, strokes occur due to reduced or interrupted blood supply to the brain, which is caused by blocked arteries or a burst blood vessel. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) which increases chances of strokes. People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in brain disorder.

Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period

Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 

According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden, which is expected to increase further over the coming years.

In March 2024, A long time ago, Mr. X suffered a severe motor vehicle accident. After the crash, he had brain damage, and his left foot dropped, causing him to walk on his toes.

From the outside, it appeared that only the left foot drop and some cognitive and memory impairments were the only consequences of the accident to Mr. X, but this was not true. Mr. X underwent an MRI examination in February 2022, which showed bilateral encephalomalacia.

According to research released in March 2024, household chemicals can impede oligodendrocyte development – cells responsible for myelin production within the human brain.

Encephalomalacia Market Segmentations

The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).  

On the basis of the diagnosis, it is segmented into blood test, brain scans, and others. A brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).

On the basis of the treatment, it is segmented into medical treatment, surgery, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories, and others.

Encephalomalacia Market Regional Analysis

The Americas dominate the global encephalomalacia market owing to well-developed technology, increasing prevalence of brain disorder, high health care spending, and increasing government support for research & development in the healthcare sector. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the encephalomalacia market in this region.

Europe holds the second position in the global encephalomalacia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.

The Asia Pacific is the fastest growing encephalomalacia market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the encephalomalacia market growth in this region.   

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Encephalomalacia Market Key Players

Some of key the players in the market are: 

• Fujifilm Holdings (Japan)


• GE Healthcare (U.S.)


• Siemens Healthcare(U.S.)


• Philips Healthcare (U.S.)


• Shimadzu Corporation (Japan)


• Toshiba Medical Systems Corporation (Japan)


• Carestream Health (U.S.)


• Nihon Kohden Corporation (Japan)


• Electrical Geodesics Inc. (U.S.)


• Masimo Corporation (U.S.)


• Hologic (U.S.)


• Esaote (Italy)

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Intended Audience

• 
  

  Pharmaceutical and Biotechnological Companies

  
  


• 
  

  Research and Development (R&D) Companies

  
  


• 
  

  Ambulatory Care Centers

  
  


• 
  

  Academic Institutes and Universities

  
  


• 
  

  Market Research and Consulting Service Providers

  
  


• 
  

  Potential Investors